Famciclovir reduces viral mucosal shedding in HSV-seropositive persons

Sexually Transmitted Diseases

Volumn 34, Issue 11, 2007, Pages 900-907

  Leone, Peter ^a   Warren, Terri ^b   Hamed, Kamal ^c   Fife, Kenneth ^d   Wald, Anna ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Westover Heights Clinic   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; PLACEBO; VALACICLOVIR; VIRUS DNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; GENITAL HERPES; GENITAL SYSTEM; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NAUSEA; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; SINUSITIS; STATISTICAL SIGNIFICANCE; VIRUS SHEDDING;

2-AMINOPURINE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CROSS-OVER STUDIES; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRUS SHEDDING; WASHINGTON;

EID: 34547757169     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e318063c749     Document Type: Article

References (24)

1. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964-973.
2. Wald A. Herpes simplex virus type 2 transmission: risk factors and virus shedding. Herpes 2004;11 (Suppl 3):130A-137A.
3. Koelle DM, Benedetti J, Langenberg A, et al. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116:433-437.
4. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985; b12:33-39.
5. Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770-775.
6. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-850.
7. Wald A, Krantz E, Selke S, et al. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis 2006; 194:42-52.
8. Cherpes TL, Meyn LA, Hillier SL. Cunnilingus and vaginal intercourse are risk factors for herpes simplex virus type 1 acquisition in women. Sex Transm Dis 2005; 32:84-89.
9. Lafferty WE, Downey L, Celum C, et al. Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis 2000; 181:1454-1457.
10. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003; 30:797-800.
11. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004; 190:1374-1381.
12. Wald A, Zeh J, Barnum G, et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996; 124:8-15.
13. Wald A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006; 33:529-533.
14. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
15. Earnshaw DL, Bacon TH, Darlison SJ, et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992; 36:2747-2757.
16. Vere Hodge RA, Sutton D, Boyd MR, et al. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother 1989; 33:1765-1773.
17. Ashley RL, Militoni J, Lee F, et al. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988; 26:662-667.
18. Ashley RL, Corey L. Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus. J Clin Invest 1984; 73:681-688.
19. Corey L, Huang ML, Selke S, et al. Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. J Med Virol 2005; 76:350-355.
20. Jerome KR, Huang ML, Wald A, et al. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol 2002; 40:2609-2611.
21. Sacks SL. Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. J Infect Dis 2004; 189:1341-1347.
22. Sizemore JM Jr, Lakeman F, Whitley R, et al. The spectrum of genital herpes simplex virus infection in men attending a sexually transmitted disease clinic. J Infect Dis 2006; 193:905-911.
23. Kim HN, Meier A, Huang ML, et al. Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men. J Infect Dis 2006; 194:420-427.
24. Wald A, Ericsson M, Krantz E, et al. Oral shedding of herpes simplex virus type 2. Sex Transm Infect 2004; 80:272-276.